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Allergic rhinitis affects 10-30% of the population, negatively 
impacting one’s quality of life and productivity. It has been 
associated with sinusitis, otitis media, sleep disorders, and 
asthma. Rupatadine is a second generation antihistamine with 
increased affinity to histamine receptor H1; it is also a potent 
PAF (platelet-activating factor) antagonist. It starts acting quite 
quickly, offers long lasting effect, and reduces the chronic 
effects of rhinitis. Aim: this study aims to assess the efficacy 
and safety of rupatadine in the treatment of persistent allergic 
rhinitis. Materials and method: this is a multi-centric open 
prospective study. This study included 241 patients from 13 
centers in Brazil and was held between October of 2004 and 
August of 2005. Signs and symptoms of rhinitis and tolerance 
to medication were analyzed after one and two weeks of 
treatment. Results: reduction on general scores from 8.65 to 
3.21 on week 2 (p<0.001). All signs and symptoms improved 
significantly in the first day of treatment (p<0.001), except 
for nasal congestion and secretion, which improved from the 
second day of treatment (p<0.001). Adverse events occurred 
in 19.9% of the cases, 27.7% on week 1. Conclusion: 
rupatadine effectively controls persistent allergic rhinitis; it 
is safe and presents low incidence of side effects.
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INTRODUCTION
Persistent allergic rhinitis is a disease of variable 
prevalence that affects 10-25% of the world’s popula-
tion1, getting to as high as 30% in some populations2,3. 
The last 20 years saw a progressive increase in the global 
prevalence of the disease, resulting in greater health care 
expenditure4. Persistent allergic rhinitis is not a fatal dise-
ase, but it brings about significant clinical complications 
as it impairs patient quality of life, productivity and social 
life1. Rhinitis is an important predisposing factor for other 
conditions such as sinusitis and otitis media3; it may also 
induce or worsen sleep disorders and impact cranial-facial 
development in children4, apart from being intrinsically 
associated with asthma.
Allergic rhinitis is an immune-mediated disease in 
which mast cells and basophils initially respond to the tri-
ggering stimulus by inducing degranulation and release of 
inflammation mediators such as histamine after an antigen 
antibody reaction with IgE. Further on other cytokines are 
released, such as IL-4, IL-5, IL-6, IL-8, TNF-alpha, GM-CSF, 
RANTES, eotaxins, and PAF (platelet-activating factor) to 
maintain the inflammatory process.5-9
From the clinical standpoint, allergic rhinitis can 
be categorized into four subgroups (mild intermittent, 
moderate/severe intermittent, mild persistent, moderate/
severe persistent)1. The intermittent manifestations can 
interrupt the triggered inflammatory process and return to 
the baseline status, but the persistent forms keep the pro-
inflammatory mechanisms active with the participation of 
T-cells in a response mediated by lymphocyte Th210. In 
these cases, therapy based exclusively on antihistamines 
may not be enough, as other sites of the inflammatory 
process may require attention.
Rupatadine is a second generation antihistamine 
and a potent PAF antagonist with high affinity for recep-
tor H111. These characteristics grant it fast action, long 
duration of effects, and reduction of the effects that sus-
tain inflammation, traits that could turn it into the ideal 
medication for patients with persistent allergic rhinitis and 
active inflammatory process.
Studies on antihistamines are usually conducted in 
countries where the presence of seasonal rhinitis is quite 
significant. However, as Brazil is a tropical country in whi-
ch the seasons are not so well-defined, seasonal rhinitis is 
not as prevalent as persistent rhinitis and rhinitis caused 
by occupational exposure. This environmental trait may 
imply in pathophysiological differences, with predominant 
Th2 inflammatory response types mediated by cytokines 
such as eotaxins, RANTES and PAF9,12. Therefore, the usual 
antihistamines may not be as effective here as found in 
studies carried out in Europe and the United States. On the 
other hand, antihistamines such as rupatadine that present 
both antihistamine and anti-PAF effect may be quite effec-
tive in populations with a similar profile to that of Brazil. 
Rupatadine is a new antihistamine and, for that reason, 
has not been targeted by a significant number of studies. 
This is the first study done in Brazil with this new antihis-
tamine. It is relevant that multicentric studies be carried 
out in various places with different populations, so that 
efficacy and tolerability are tested in specific populations.
This study aims to assess clinical efficacy and safety 
of rupatadine in a 2-week treatment program designed for 
patients with persistent allergic rhinitis.
MATERIALS AND METHOD
 
Studied population
Sample size was calculated taking into account 
an expected reduction of rhinitis signs and symptoms in 
treated patients ranging between 45% and 68% as seen 
in previous trials, and using the formula for population 
proportion of unknown size. Seventy-two patients had to 
be included in the study to allow for a confidence interval 
of 95% and a variation of 11.5% in population proportion.
Enrollment criteria: patients had to be above 12 
years of age and diagnosed with moderate to severe per-
sistent allergic rhinitis (according to the ARIA criteria) for 
at least one year, presenting symptoms for more than four 
days a week for at least four weeks, impacted quality and 
quantity of sleep, and interference upon daily life activities. 
Patients were enrolled in the study only after they or their 
guardians signed a Free Informed Consent Term.
Exclusion criteria: pregnancy, nursing patients, 
patients taking other medications for the treatment of 
rhinitis (oral steroids for one month, topical steroids for 
one week, leukotriene receptor antagonists (LTRA) for 
one week, other antihistamines for 15 days), patients with 
acute airway disorders such as upper airway infections 
or non-allergic eosinophilic rhinitis, drug-induced rhinitis 
or patients with other conditions that could potentially 
introduce confusion in result interpretation, excessively 
deviated septum, nasal polyps, any nasal malformation, 
or who present current evidences of clinically significant 
diseases of a hematopoietic, cardiovascular, hepatic, renal, 
neurologic, psychiatric, autoimmune, or respiratory nature 
or severe atopic dermatitis.
 
Study design
This is a multicentric open prospective study carried 
out to assess the clinical response of patients with mode-
rate to severe perennial allergic rhinitis after two weeks of 
treatment with rupatadine fumarate. Patients were selected 
from 13 centers in Brazil between October of 2004 and 
August of 2005, covering spring, summer, fall and winter, 
i.e., all seasons of the year. Some patients were assessed 
in southern states of Brazil, located in temperate latitudes 
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where seasons are better defined. Patients had to provide 
written consent to participate in the study, meet enrollment 
criteria and have no exclusion criteria before they were 
assessed for their baseline parameters to allow the analysis 
of medication efficacy and safety; they were then given a 
diary of symptoms and the medication itself. Patients were 
reassessed one week and two weeks into the protocol. 
All parameters were looked into during the two follow-
up visits so as to assess drug efficacy and safety. Patients 
were advised to take the medication in the morning as 
they woke up and to write down the symptoms they had 
every day in the morning as they got up (before they took 
the medication) and at night before they went to bed.
The study was approved by the Ethics Committees 
of all involved institutions under the principles of the 
Declaration of Helsinki.
 
Efficacy assessment
Patients were asked to rate the rhinitis symptoms 
they experienced (nasal obstruction, nasal pruritus, snee-
zing, and nasal dripping) on a daily basis in a scale ranging 
from 0 (no symptoms) to 3 (hard-to-tolerate symptoms 
leading to adverse impact on everyday life and/or sleep). 
General symptoms (nasal obstruction, nasal pruritus, sne-
ezing, and nasal dripping) and signs (turbinate coloration, 
presence of nasal discharge, and turbinate edema intensity) 
were also analyzed one and two weeks into treatment 
during medical visits. Assessment of signs was performed 
through observation during ENT physical examination 
done using a nasal speculum, and scores were assigned 
from 0 (normal) to 3 (anemic/bluish turbinate; profuse 
nasal discharge and drainage; one or two congested nasal 
fossae due to turbinate edema). Each sign was assessed 
separately, based on the sign and symptom score protocol 
described above3. Patient general impressions over clinical 
efficacy were also considered in the form of the diary they 
filled up in the morning and at night.
 
Safety assessment
Safety assessment was carried out through a des-
criptive analysis of the adverse events observed during 
the study with possible, probable or defined causal rela-
tionships defined for the studied medication, according 
to the terminology for adverse reactions from the World 
Health Organization (WHO-ART); causality was assessed 
based on the Kasch-Lasagna algorithm. Systemic safety 
tests were carried out (CBC, creatinine, total bilirubin, AST 
and ALT). Researchers’ impressions were also analyzed for 
patient tolerability based on the score given on the last 
visit two weeks into treatment.
 
Statistical analysis
The data sets are presented in the form of mean 
values and standard deviations, followed by a descrip-
tive analysis. Quantitative parameters were analyzed in 
terms of variance for repeated numbers, or the Friedman 
non-parametric test, adopting a significance level of 0.05 
(p<0.05). Demographic results and clinical characteristics 
are analyzed for the population intended for treatment 
(PIT), efficacy is analyzed for the population following the 
protocol (PP), and safety is analyzed for the population 
intended for treatment (PIT).
RESULTS
 
Demographic data
A total of 241 patients applied for enrollment in the 
study. Seventy-five of them were excluded. Out of the 166 
enrolled patients (PIT sample), 27 were excluded due to 
non-compliance, dropping out, or protocol violation (Fig. 
1); 139 patients remained in the study (PP sample). Six of 
the remaining 139 interrupted the treatment due to preg-
nancy, upper airway infection, and xerostomia (Fig. 1).
Table 1 shows the overall distribution of patient 
demographic traits at the time of enrollment and patient 
clinical characteristics.
Figure 1. Flowchart - patient enrollment and follow-up.
Overall efficacy
Efficacy assessment comprised the separate and 
combined evaluation of each sign and symptom of allergic 
rhinitis observed after one and two weeks of treatment, 
as well as the time it took for patients to improve from 
symptoms as recorded in the diary.
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Table 1. Baseline clinical and demographic characteristics (before enrollment) PIT sample
Rupatadine n = 166
Gender - n (%)  
Male 61 (36.7)
Female 105 (63.3)
Age (years) - mean ± SD 26.4 ± 11.2
Ethnicity - n (%)  
White 109 (65.7)
Black 22 (13.2)
Brown 33 (19.9)
Asian 2 (1.2)
Time with allergic rhinitis (years) - mean ± SD 11.3 ± 8.7
Allergic rhinitis intensity total score - mean ± SD 9.2 ± 1.6
Smoking - n (%) 7 (4.2)
Physical activity (at least twice a week) - n (%) 53 (31.9)
Previous anti-allergy medication * - n (%) 105 (63.3)
Concurrent diseases - n (%) 63 (38.0)
Weight (kg) - mean ± SD 61.9 ± 14.0
Height (cm) - mean ± SD 163.7 ± 9.7
Turbinate coloration - n (%)  
Reddish / pale pink 38 (22.9)
Red / pale 105 (63.3)
Anemic / bluish 23 (13.8)
Absent turbinate edema - n (%) 2 (1.2)
Absent turbinate discharge - n (%) 9 (5.4)
* - Previous use of the following anti-allergic drugs was reported: 75 (45.2%) antihistamines, 81 (48.8%) steroids, 3 (1.8%) adrenergic agents, 12 
(7.2%) combined steroids and adrenergic agents, 1 (0.6%) chromone, and 2 (1.2%) immunotherapy.
Table 2. Two-week evolution of signs and symptoms
Evaluation - mean + SD Treatment period
Week 0 
(pre-treatment)
Week 1 Week 2
Nasal pruritus 2.19 + 0.7 0.83 + 0.8 * 0.68 + 0.8 * #
Sneezing 2.22 + 0.7 0.66 + 0.8 * 0.50 + 0.7 * #
Nasal dripping 2.18 + 0.7 1.21 + 0.9 * 0.96 + 0.9 * #
Nasal obstruction 2.07 + 0.7 1.18 + 0.9 * 1.08 + 0.8 *
Total score 8.65 + 1.5 3.88 + 2.5 * 3.21 + 2.5 * #
Turbinate coloration 1.89 + 0.6 1.42 + 0.7 * 1.21 + 0.7 *
Turbinate edema 1.93 + 0.6 1.45 + 0.7 * 1.32 + 0.7 *
Turbinate discharge 1.62 + 0.6 0.88 + 0.7 * 0.71 + 0.7 * #
* p <0.001 in relation to week 0 (pre-treatment); # p<0.001 in relation to the first week of treatment.
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Overall symptom scores were significantly reduced 
from 8.65 to 3.88 after one week of treatment, and to a 
further 3.21 after two weeks of therapy (p<0.001) (Graph 
1). All analyzed symptoms improved significantly after 
one week; only nasal obstruction did not show incremen-
tal improvement between the first and second week of 
treatment. Clinical nasal signs were significantly reduced 
after one week of treatment (p<0.001), but additional 
improvements were not observed after the second week 
of treatment (Table 2).
Patients reported that all symptoms improved 
significantly right after the first day of treatment both in 
the morning and at night (p<0.001), except for nasal obs-
truction and discharge; these two only improved at night 
starting on the second day of treatment (p<0.001) (Graph 2)
Safety
The study revealed an overall 19.9% prevalence of 
adverse events; in the first week of treatment this same 
prevalence rate amounted to 27.7%. The most relevant 
Graph 1. Percent decrease on overall symptom scores throughout the 
study. Mean values + standard deviation.
Pre-treatment
* p<0.05 in relation to pre-treatment, § P<0.05 in relation to week 1.
Graph 2. Daily evolution of nasal symptoms within the first seven days 
of treatment.
* - p < 0.001 when compared to morning of day 1, § - p < 0.001 when 
compared to afternoon of day 1
Table 3. Adverse reactions observed during the study
Adverse reactions
Week 1 (n = 162) 
# patients (%)
Week 2 (n = 161)
Increased appetite 4 (2.5 %) 5 (3.1%)
Increased indirect bilirubin 0 2 (1.2%)
Increased total bilirubin 0 1 (0.6%)
Bitter mouth 1 (0.6%) 0
Dry mouth 4 (2.5%) 2 (1.2%)
Dry mouth and cracked lips 0 1 (0.6%)
Headache 6 (3.7%) 3 (1.9%)
Constipated bowel 0 1 (0.6%)
Impotence 0 1 (0.6%)
Nausea 1 (0.6%) 0
Epigastric burning sensation 1 (0.6%) 0
Skin rash 1 (0.6%) 0
Sleepiness 31 (19.1%) 23 (14.3%)
Dizziness 2 (1.2%) 1 (0.6%)
Vomiting 1 (0.6%) 0
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adverse events observed were sleepiness, increased appe-
tite (3.1%), dry mouth (2.5%), and headache (3.7%). All 
such events had their prevalence reduced by the end of 
the study (Table 3).
Eighteen (11.1%) patients suffered from sleepiness 
throughout the entire study; 13 (8.0%) patients had sleepi-
ness only during the first week; and only 5 (3.1%) patients 
had no sleepiness in the first week only to present it in 
the second week of treatment. Only three (1.85%) patients 
had severe sleepiness to the point of compromising their 
daily activity, and 14 (8.64%) had moderate sleepiness 
episodes. All remaining adverse events reported as mild 
and not commented above are shown on Table 3.
DISCUSSION
This study has proven the efficacy of rupatadine in 
treating patients with persistent allergic rhinitis, reducing 
nasal symptoms, improving signs secondary to mucosal 
inflammation with sustained and even improving results 
after two weeks of treatment. The study has also shown 
that the rate of adverse events is relatively low and of little 
clinical significance.
Studies on antihistamines are usually conducted in 
countries where the presence of seasonal rhinitis is quite 
significant. However, as Brazil is a tropical country in whi-
ch the seasons are not so well-defined, seasonal rhinitis is 
not as prevalent as persistent rhinitis and rhinitis caused 
by occupational exposure. This environmental trait may 
imply in pathophysiological differences, with predominant 
Th2 inflammatory response types mediated by cytokines 
such as eotaxins, RANTES and PAF9,12. Therefore, the usual 
antihistamines may not be as effective here as found in 
studies carried out in Europe and the United States. On 
the other hand, antihistamines such as rupatadine that 
present both antihistamine and anti-PAF effect may be 
quite effective in populations with a similar profile to 
that of Brazil13. Therefore, the main purpose of this study 
was to assess the degree of efficacy of an antihistamine 
with anti-PAF effect without however comparing it against 
other therapies. For this reason, the study was designed 
to assess response along time (two weeks) without using 
a control group.
From the demographic standpoint, the studied po-
pulation was mainly composed of Young patients with a 
slight predominance of females (63.3% against 36.7% of 
males), with different ethnic backgrounds and moderate 
persistent rhinitis (symptom score of 9.2 out of 12). This 
patient profile matches the population distribution obser-
ved in the large Brazilian centers at which this study was 
carried out 14.
Classically, ordinary antihistamines do not offer 
good clinical response in controlling signs and symptoms 
such as nasal obstruction, edema and hyperemia that 
occur secondary to persistent inflammation15. This study 
showed that, contrary to what has been observed for other 
antihistamines16, rupatadine is effective in controlling all 
symptoms associated with rhinitis and provides for marked 
reduction on overall symptom scores. Improvements were 
statistically significant for nasal obstruction, even at night, 
as reported by the patients. This shows that rupatadine 
can effectively manage the persistent symptoms of allergic 
rhinitis even in cases where symptoms such as edema and 
nasal congestion persist for several months. Allergic nasal 
obstruction is caused by mucosal inflammation and edema, 
with engorged sinus capacitance vessels, rhinorrhea and 
increased mucus production, one of the symptoms more 
closely related to chronic nasal mucosa inflammation. 
Antihistamines are usually considered to be less effective 
in treating nasal obstruction than other symptoms of aller-
gic rhinitis. Some other newer antihistamines have been 
associated with nasal obstruction relief16. Other studies 
on rupatadine have reported similar results, as this is a 
potent histamine receptor antagonist with good in-vitro 
anti-inflammatory effect17,18.
This study showed that rupatadine offers effective 
response in the treatment of persistent allergic rhinitis 
added by with two other important factors: fast response 
onset - observed right between the first and second day 
of treatment - and sustained improvements throughout 
the two-week period.
Other antihistamines do not offer consistent respon-
se against the main symptoms of allergic rhinitis. Therefore, 
patients often respond only partially to treatment and re-
quire additional drugs or even more time to control their 
symptoms19. The better management of signs and symp-
toms associated with persistent nasal inflammation offered 
by rupatadine may stem from the fact that rupatadine is 
a potent PAF antagonist, as shown in other studies20,21. 
However, the design of this study never meant to assess 
the role of rupatadine as a PAF antagonist; more studies 
should be conducted to assess the relevance of such trait 
for the treatment of human beings.
This study showed that there was a slight impro-
vement on the symptom scores between the first and 
second week of treatment, and that treatment response 
was sustained by the end of treatment. Although this was 
only a two-week long study, sharper responses in symptom 
reduction were observed within the first week of therapy, 
as the medication acted quite rapidly and achieved close 
to full effect within seven days. On the second part of the 
study symptom mitigation was not as marked, as they had 
been dramatically reduced by then.
Prevalence of adverse events was generally low; the 
most relevant ones were related to sleepiness, although this 
is a relatively difficult factor to be analyzed. Sleepiness is a 
symptom of high prevalence in the population in general, 
and is usually a consequence of one’s life style. When 
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asked more actively about the presence of sleepiness, 
patients tend to overrate the symptom, thus leading to 
an overestimation of the relationship between sleepiness 
and the medication. On the other hand, it is known that 
antihistamines do introduce a certain degree of sleepiness. 
This study did not have a control group, and it is therefore 
impossible to tell how much sleepiness derived from the 
medication itself and how much originated from patients 
overrating the symptom. However, most patients had mild 
symptoms that did not interfere with their productivity at 
work or adversely impact their social lives. Additionally, 13 
(8%) patients improved from sleepiness after the first week 
of treatment, indicating that the effects of rupatadine upon 
the central nervous system are mild, not very prevalent 
(+10%), and that they tend to improve with use as also 
shown in other studies22. No adverse cardiac events were 
reported in the study, an important addition to the safety 
of rupatadine, as arrhythmia cases have been described 
in association with other antihistamines as terfenadine.
All other adverse events related to the use of rupa-
tadine had similar prevalence rates to those reported in 
other studies, including what was observed in the control 
groups of these studies, making it even harder to interpret 
the occurrence of such adverse events. However, for safety 
reasons the observed events should be seen as potentially 
connected to the medication.
CONCLUSION
No control groups were defined in this study to 
compare rupatadine against other drugs or placebo. Thus, 
the assessment of efficacy is subject to other factors, such 
as the natural history of the disease or placebo effect.
Therefore, we may conclude that even in the Bra-
zilian population rupatadine can effectively manage the 
signs and symptoms of moderate persistent allergic rhinitis, 
and that its effect lasted for the period of two weeks. We 
may also add that rupatadine in therapeutic dosages is 
safe and offers low side effect rates.
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